Nightstar Therapeutics (NITE) Expected to Post Q2 2018 Earnings of ($0.77) Per Share

Nightstar Therapeutics (NASDAQ:NITE) – Investment analysts at Leerink Swann issued their Q2 2018 earnings per share estimates for shares of Nightstar Therapeutics in a research note issued on Wednesday, April 11th. Leerink Swann analyst J. Schwartz anticipates that the company will post earnings per share of ($0.77) for the quarter. Leerink Swann also issued estimates for Nightstar Therapeutics’ Q4 2018 earnings at ($0.88) EPS, FY2018 earnings at ($1.66) EPS and FY2019 earnings at ($1.75) EPS.

How to Become a New Pot Stock Millionaire

Other equities research analysts have also recently issued reports about the stock. Chardan Capital initiated coverage on shares of Nightstar Therapeutics in a research report on Wednesday, January 3rd. They set a “buy” rating and a $40.00 price objective for the company. Mizuho initiated coverage on shares of Nightstar Therapeutics in a research report on Tuesday, February 27th. They set a “buy” rating and a $20.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Nightstar Therapeutics in a research report on Wednesday, March 7th. Finally, Zacks Investment Research cut shares of Nightstar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 7th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Nightstar Therapeutics has an average rating of “Buy” and a consensus price target of $28.50.

Nightstar Therapeutics stock opened at $14.60 on Monday. The firm has a market cap of $409.14 and a PE ratio of -8.96. Nightstar Therapeutics has a 12-month low of $10.01 and a 12-month high of $24.93.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Essex Investment Management Co. LLC purchased a new stake in Nightstar Therapeutics in the fourth quarter valued at $1,771,000. Ameriprise Financial Inc. purchased a new stake in Nightstar Therapeutics in the third quarter valued at $5,761,000. Finally, Nationwide Fund Advisors purchased a new stake in Nightstar Therapeutics in the third quarter valued at $1,196,000. 29.06% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Nightstar Therapeutics (NITE) Expected to Post Q2 2018 Earnings of ($0.77) Per Share” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2018/04/16/nightstar-therapeutics-nite-expected-to-post-q2-2018-earnings-of-0-77-per-share.html.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.

Earnings History and Estimates for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply